STOCK TITAN

Relay Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Relay Therapeutics, Inc. (Nasdaq: RLAY) announced that Sanjiv Patel, M.D., President and CEO, will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024. The presentation will be webcast live and may be accessed through Relay Therapeutics’ website. An archived replay of the webcast will be available for up to 30 days following the event.
Positive
  • None.
Negative
  • None.

CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that Sanjiv Patel, M.D., President and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 2:15 p.m. PT.

The presentation will be webcast live and may be accessed through Relay Therapeutics’ website under Events in the News & Events section through the following link: https://ir.relaytx.com/news-events/events-presentations. An archived replay of the webcast will be available for up to 30 days following the event.

About Relay Therapeutics

Relay Therapeutics is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of complementary techniques and technologies, Relay Therapeutics aims to push the boundaries of what’s possible in drug discovery. Its Dynamo™ platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics’ initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit www.relaytx.com or follow us on Twitter.

Contact:
Megan Goulart
617-545-5526
mgoulart@relaytx.com

Media:
Dan Budwick
1AB
973-271-6085
dan@1abmedia.com


The conference is on January 9, 2024.

Sanjiv Patel, M.D., President and CEO of Relay Therapeutics, Inc.

The live webcast can be accessed through Relay Therapeutics’ website under Events in the News & Events section.

The archived replay will be available for up to 30 days following the event.
Relay Therapeutics Inc

NASDAQ:RLAY

RLAY Rankings

RLAY Latest News

RLAY Stock Data

Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Health Technology, Pharmaceuticals: Major, Biotechnology, Manufacturing, Biological Product (except Diagnostic) Manufacturing
US
Cambridge

About RLAY

relay therapeutics is building the world’s first dedicated drug discovery platform centered on protein motion to discover and develop new medicines that will make a transformative difference for patients. by placing protein motion at the heart of drug discovery, relay is pursuing what it believes will be a fundamental paradigm shift within the pharmaceutical industry, ushering in a new generation of drugs with the potential to improve and extend the lives of millions of patients. headquartered in cambridge, mass., relay therapeutics is a private company launched in 2016. to date, relay therapeutics has raised $120m in financing from third rock ventures, bvf partners, gv (formerly google ventures), an affiliate of d.e. shaw research, casdin capital, ecor1 capital, section 32 and alexandria venture investments. our world-class team is equal parts bright and bold, with a shared passion for working in intellectually stimulating environments. if you're creative, collaborative and passionate